EP 42 | GLP-1s Explained: Breakthrough Therapy, Budget Disruptor, or Both?
GLP-1 medications have moved from diabetes treatment to a cultural phenomenon in record time. But beyond the headlines and celebrity endorsements lies a far more complex story. In Episode 42, Dr. Randy Vogenberg breaks down what GLP-1s actually are, how they function in the body, and why they are reshaping conversations around obesity, metabolic syndrome, cardiovascular risk, and employer health plan budgets. From Ozempic and Wegovy to emerging alternatives, this episode explores the clinical promise,



